Premium
Immunoglobulin A1 protease: A new therapeutic candidate for immunoglobulin A nephropathy
Author(s) -
XIE LINSHEN,
HUANG JUN,
QIN WEI,
FAN JUNMING
Publication year - 2010
Publication title -
nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 61
eISSN - 1440-1797
pISSN - 1320-5358
DOI - 10.1111/j.1440-1797.2010.01278.x
Subject(s) - mesangium , medicine , glomerulonephritis , nephropathy , immunoglobulin a , antibody , pathogenesis , immunology , glomerular mesangium , protease , immunoglobulin g , enzyme , kidney , biology , endocrinology , biochemistry , diabetes mellitus
Immunoglobulin A nephropathy (IgAN), characterized by predominant or exclusive deposition of IgA1 in glomerular mesangium, is the most common primary glomerulonephritis worldwide. At present, the treatment is always limited due to the incomplete understanding of the pathogenesis of IgAN. Mesangial deposited IgA1 is the common final pathway leading to glomerulonephritis and renal injury. IgA1 protease, a proteolytic enzyme with strict substrate specificity for human IgA1, may be an effective therapeutic candidate for IgAN by removing the mesangial deposited IgA1.